[Form 4] AtriCure, Inc. Insider Trading Activity

Rhea-AI Filing Summary

On this Form 4, AtriCure (ATRC) Chief Scientific Officer Vinayak S. Doraiswamy reported an open-market sale of 2,500 common shares on 08/05/2025 at $36.58 per share, yielding roughly $91 K in proceeds. After the transaction, he directly owns 71,872 shares, down about 3.4% from 74,372, leaving a stake worth ~$2.6 M at the sale price. No derivative trades were disclosed, and the filing cites no Rule 10b5-1 plan. Aside from this single sale, the document contains no financial results, guidance, or additional corporate events.

Positive

• Insider retains 71,872 shares, indicating continued personal investment in ATRC.

Negative

• Insider sale of 2,500 shares at $36.58 could be perceived as a mild bearish signal if followed by further disposals.

Insights

Securities Analyst

TL;DR: Small insider sale; limited signaling value.

The 2,500-share sale equals roughly 0.07% of AtriCure’s 3.7 M share float and only 3.4% of the insider’s personal holdings. Given the modest size and lack of accompanying derivatives or programmatic trading disclosure, I view the move as routine portfolio diversification rather than a bearish signal. Liquidity impact is negligible and does not alter the company’s investment thesis or fundamentals.

Portfolio Manager

TL;DR: Transaction is immaterial; monitor for pattern.

While insider selling often draws attention, the dollar value (<$100 K) and remaining sizeable ownership suggest continued alignment with shareholders. I classify this as neutral but will watch for successive sales, particularly by multiple executives, which could indicate shifting sentiment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doraiswamy Vinayak

(Last) (First) (Middle)

7555 INNOVATION WAY

(Street)

MASON OH 45040-9695

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/05/2025		S		2,500	D	$36.58	71,872	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Vinayak S. Doraiswamy	08/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many AtriCure (ATRC) shares did the executive sell?

The Chief Scientific Officer sold 2,500 common shares.

At what price were the ATRC shares sold?

The shares were sold at $36.58 per share.

What is the executive’s remaining ATRC shareholding?

Post-sale, the executive directly owns 71,872 shares.

Does this Form 4 mention a Rule 10b5-1 trading plan?

No, the filing does not reference a 10b5-1 plan.

Were any derivative securities involved in this transaction?

No derivative securities were reported in this Form 4.